Nancy L. Bartlett

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

Roland Schmitz, George W. Wright, Da Wei Huang et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Axicabtagene Ciloleucel +9

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text